Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kura Oncology reports Q4 loss, highlights ziftomenib's AML potential

Kura Oncology's Q4 2022 performance reflects increased R&D expenses and a net loss, offset by a strong cash position supporting operations.
The company's focus on ziftomenib's positive trial data, combination studies, and patient-centric strategies positions it for future growth.
Challenges lie in managing treatment complexities, strategic resource allocation, and balancing commercial value with patient benefit.
Opportunities include upcoming milestones, exploration of combination therapies, and regulatory advancements for ziftomenib.

Kura Oncology sees positive results with ziftomenib in Q1

Kura Oncology's Q1 2023 earnings call highlighted the promising performance of ziftomenib in AML patients, supported by strong Phase 1 trial data and strategic plans for combination studies.
While facing challenges in competitive differentiation and trial execution, the company's financial stability and focus on methodical drug development underscore its long-term potential.
Opportunities lie in achieving key milestones, exploring new therapeutic applications, and leveraging a competitive edge in the menin inhibitor space for future growth and success.

Kura Oncology reports Q2 loss, sees growth in clinical trials

Kura Oncology's Q2 2023 performance reflects increased expenses but promising clinical outcomes, with strong enrollment and positive data in key trials.
Strategic strengths lie in combination studies, diversified indications, and positive trial results, positioning the company for future growth and market expansion.
Challenges include resource constraints, research prioritization, and evolving resistance issues, necessitating adaptive strategies and efficient resource management.
Opportunities for Kura Oncology include collaborations, out-licensing, and program expansions, offering avenues for operational efficiency and revenue growth.

Kura Oncology's ziftomenib shows promise in acute leukemias, financials stable

Kura Oncology's Q3 performance reflects increased expenses but maintains a strong financial position.
The company's lead drug candidate, ziftomenib, shows promise in acute leukemias, with positive response rates.
Strategic strengths include progress with menin inhibitors, successful combination approaches, and clinical collaborations.
Challenges lie in meeting enrollment timelines, addressing efficacy questions, and balancing program investments.

Kura Oncology reports promising clinical data and financial stability

Kura Oncology's Q4 2023 performance showcased positive clinical data and financial stability, positioning the company well for future growth.
While challenges in data interpretation and differentiation exist, opportunities in milestone achievements and patient-focused therapies are on the horizon.
The company's strategic focus on early therapy lines and combinability of menin inhibitors highlight its strengths in the competitive market landscape.

Kura Oncology reports promising results for ziftomenib in Q1

Kura Oncology's Q1 2024 performance reflects increased R&D expenses and promising results for ziftomenib.
Strengths lie in FDA support, encouraging safety profiles, and ongoing combo dose escalation trials.
Challenges include patient characteristics impacting therapy duration and strategic resource allocation.
Opportunities include upcoming milestones, solid tumor data disclosure, and competitor monitoring for market insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.

Why Kura Oncology Stock Is Sliding Today

The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Inc's (NASDAQ: KURA) cancer drugs following a patient's death in a clinical trial. Kura reported that the Phase 1b study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probe the death.

See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial

Management to host webcast and conference call today at 8:30 a.m. ET Management to host webcast and conference call today at 8:30 a.m. ET

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Credit Suisse 30th Annual Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:30 p.m. ET / 12:30 p.m. PT on Tuesday, November 9, 2021.

Kura Oncology to Participate in Credit Suisse Healthcare Conference

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial results after the close of U.S. financial markets on Thursday, November 4, 2021. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Third Quarter 2021 Financial Results

SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary. Ms. Bair joins Kura with more than 25 years of combined in-house and law firm experience, most recently as General Counsel at Athenex.

Kura Oncology Appoints Teresa Bair as Chief Legal Officer

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2021 Results - Earnings Call Transcript

– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 –

Kura Oncology Reports Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of industry veteran Helen Collins, M.D., to its board of directors. Dr. Collins served as Chief Medical Officer at Five Prime Therapeutics, where she oversaw the development of bemarituzumab, a first-in-class anti-FGFR2b antibody for the treatment of patients with gastric cancer.

Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors –

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose –

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on Thursday, June 17, 2021.

Kura Oncology to Participate in JMP Securities Life Sciences Conference

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Carol Schafer to its board of directors, effective June 3, 2021. Ms. Schafer has more than 25 years of experience in healthcare investment banking, most recently as Vice Chair of Equity Capital Markets at Wells Fargo Securities.

Kura Oncology Appoints Carol Schafer to Board of Directors

American Woodmark

Arena Pharmaceuticals

Atreca

Cannae Hlds

Dominion Energy

ESCO Technologies

FutureFuel

Heartland Express

Intelligent Systems

Kiniksa Pharmaceuticals Ltd

Madrigal Pharmaceuticals

NewMarket

PG&E

Premier

SelectQuote

Theravance Biopharma

Invesco DB US Dollar Index Bullish Fund

Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since March.

20 Short Ideas With Super-Weak Momentum

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat on Thursday, May 20, 2021 at 10:20 a.m. PT / 1:20 p.m. ET.

Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2021 Results - Earnings Call Transcript

– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window –

Kura Oncology Reports First Quarter 2021 Financial Results

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after the close of U.S. financial markets on Thursday, May 6, 2021. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report First Quarter 2021 Financial Results

– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2020 Results - Earnings Call Transcript

The FDA has designated Breakthrough Therapy status to Kura Oncology Inc's (NASDAQ: KURA) tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for head and neck cancer. The status covers recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with a variant allele frequency of more than 20% after disease progression on platinum-based chemotherapy.

Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck Cancer

– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –

Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results

SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy. Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial (AIM-HN) in this indication of high unmet need.

News for Kura Oncology Stock (KURA)